One of Montana’s largest health clinics that serves people in poverty has cut back services and laid off workers.
Arcus deprioritizes Gilead-partnered drug in prostate cancer, the latest hiccup in $1.6B collaboration
Arcus Biosciences is reducing further investment on its adenosine receptor antagonist in prostate cancer after reviewing interim data, according to its second quarter report. In